Sai Parenteral’s Limited is a pharmaceutical formulations company engaged in research, development and manufacturing of medicines. The company operates through two key verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services for domestic and international markets. Its product portfolio covers therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, analgesics and dermatology. These medicines are supplied in various dosage forms including injectables, tablets, capsules, liquid orals and ointments. The company earns revenue by selling its branded generics to hospitals, government agencies, pharmaceutical companies and distributors, while also providing CDMO services such as product development, regulatory filings and commercial manufacturing for global clients.

Sai Parenteral`s an Book Built Issue, amounting to ₹ 408.79 Crore,consisting an fresh issue of 0.73 crore shares aggregating to ₹ 285.00 crore and offer for sale of  0.32 crore shares aggregating to ₹ 123.79 crore The subscription period for the Sai Parenteral`s IPO opens on March 24, 2026, and close on March 27, 2026. The allotment is expected to be finalized on or about 30 March, 2026, Monday, and the shares will be listed on the NSE & BSE with a tentative listing date set on or about Thursday, April 02, 2026.

The Share Price Band of Sai Parenteral`s IPO is set at ₹372 to ₹392 per share  per equity share. The Market Capitalisation of the Sai Parenteral`s at IPO price of ₹392  per equity share will be ₹₹1,731.83 Cr. The lot size of the IPO is 38 shares. Retail investors are required to invest a minimum of ₹ 14,896, 1 lots ( 38 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is 14 lots ( 532 shares), amounting to ₹ 208,544.

Arihant Capital Markets Limited, the book running lead manager of the Sai Parenteral`s Ltd. while Bigshare Services Private Limited is the registrar for the issue.

Sai Parenteral`s Limited IPO GMP Today
The Grey Market Premium of Sai Parenteral`s IPO is expected to be ₹0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Sai Parenteral`s Limited IPO Live Subscription Status Today: Real-Time Update
The subscription period for the Sai Parenteral`s IPO opens on 24 March 2026

Sai Parenteral`s Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Sai Parenteral`s IPO allotment date is 30 March, 2026, Monday, Sai Parenteral`s IPO Allotment will be out on 30 March, 2026, Monday, and will be live on Registrar Website from the allotment date.
Bigshare Services Private Limited IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Sai Parenteral`s IPO from the dropdown list of IPO
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

Objectives of Sai Parenteral`s Limited IPO
Sai Parenteral`s to utilise the Net Proceeds towards the following objects:
1. ₹1,107.95 Million is required for Capacity expansion and upgradation of manufacturing facilities
2. ₹180.23 Million is required for Establishment of a new R&D Centre
3. ₹143.02 Million is required for Repayment / prepayment of certain outstanding borrowings
4. ₹330.00​​​​​​​ Million is required for Working capital requirements
5. ₹356.41 Million is required for Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
6. General Corporate Purposes.

Refer to Sai Parenteral`s Limited RHP for more details about the Company.